Navigation Links
Reverse-iT One-Step Kit, ReddyMix from ABgene

ProductsReverse-iT One-Step Kit, ReddyMix from ABgene
Company ABgene
Item Reverse-iT One-Step Kit, ReddyMix
Price 
Description The Reverse-iT™ One-Step Kit is the ultimate in convenience, sensitivity and reproducibility in RT-PCR. It has been specifically designed to streamline the RT-PCR process.

The Reverse-iT™ One-Step Kit combines the unique Reverse-iT™ Blend of RTases and ABgene®s Thermoprime Plus DNA Polymerase to provide a highly sensitive, reproducible and easy-to-use system for the detection and analysis of RNA. The kit is able to detect RNA from as little as 100 femtograms. The Reverse-iT™ Blend can be used at temperatures up to 57°C, avoiding problems caused by secondary structure in the RNA template. It also shows a better dynamic range than AMV or MMuLV. This means that increases in template concentration give rise to corresponding increases in product generated over a wider range of starting material concentrations.

The master mix format of the kit minimises reagent handling steps, reducing errors and the risk of contamination. It is supplied at a 2x concentration, providing extra flexibility for primer and template concentrations, and contains a proprietary buffer, which has been optimised for exceptional sensitivity and yield. The Reverse-iT™ Blend is provided in a separate tube, allowing negative controls without RTase to be carried out easily. The kit is also available in ABgene®s ReddyMix™ format, which contains a dye and precipitant for running samples directly on electrophoresis gels after RT-PCR.
Info ABgeneABgene
ABgene House
Blenheim Road
Epsom
Surrey KT19 9AP
UK
Customer Service: +44 (0)1372 723456
Fax Number: +44 (0)1372 741414
Web Site: http://www.abgene.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. One-Step Deparaffinization Solution from Lab Vision
2. Beacon 2000 One-Step FP Std from Invitrogen
3. ABsolute QRT-PCR SYBR Green Fluorescein Mix from ABgene
4. Thermo-Fast 96 PCR Plate, Non-Skirted from ABgene
5. ABsolute QPCR SYBR Green ROX Mix from ABgene
6. Workstation/Stacking System from ABgene
7. Extensor Hi-Fidelity PCR Enzyme from ABgene
8. SmartScan Solo from ABgene
9. Smart Scan 96 from ABgene
10. 96 Well Base Plate from ABgene
11. Lambda Control Kit from ABgene
(Date:10/15/2014)... 2014 Sandata Technologies, LLC, an industry ... care, today announced it released a case study ... Visit Verification™ Solution (EVV™)  for Quality Care Services, ... company founded in 1996 and has five locations ... The study details the challenges facing Quality ...
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
(Date:10/15/2014)... Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market releases photos and video ... Square on Monday October 13 th . ... Tunnel and angel investor Mr. Chad A. Verdi ... of NXT-ID thanked his investors and employees "for their work and ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... . . Families of thousands of victims ... receive appropriate punishment, because of a suite of technologies ... some graves, perhaps hundreds of thousands remain undiscovered. Researchers ... Oak Ridge National Laboratory are developing a method to ...
... organs in the body has shown to provide effective treatment ... Bristol researchers and published in Nature Communications , could ... carotid body a small nodule (no larger than a ... appears to be a major culprit in the development ...
... with a complex heart condition called hypertrophic cardiomyopathy (HCM) found ... for heart transplantation was greatest for those who developed this ... who also had selective inborn errors of metabolism, a group ... the body,s key metabolic processes are disrupted. The ...
Cached Biology News:September 2013 story tips 2September 2013 story tips 3Size really does not matter when it comes to high blood pressure 2Risk factors help predict outcomes for children with rare heart condition 2
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... 2014 , A major pan-European ... the delivery of care has revealed changing trends in ... in the provision of healthcare services across the continent. ... United European Gastroenterology (UEG), have been announced today and ... of the burden of GI disorders across ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6